Etude de l'evolution sous polychimiothérapie de l'etat neurologique des malades hanseniens nouvellement dépistes : résultats à 3 ans

- BECX-BLEUMINK M., BERTHED. MANNEIJE W.T.

The managment of nerve damage in the leprosy control services.

Lep. Rev., 1990, 61,1-11.

- BLOOM B.R., GODAL T.

Selective primary health care : strategies for control of disease in the developping world. V. Leprosy.

Review of Infectious Diseases, 1983, 5., 765-780.

- BODDINGUS J.

Ultrastructure of begining and progressive nerve involvement in leprosy patient.

XIe Congres International de Leprologie, Mexico, 1978, Abst. 271-276.

- BODDINGUS J.

Mechanisms of peripheral nerve damage in leprosy. Electron and light microscope studies throughout the spectrum.

Quad. Coop. Sanit., 1982, 1; 65-85.

- BOILLOT F.

Aspects actuels de la neuropathie hansenienne.

Th. Doct. Med., 1985, Grenoble.

- BOURREL P.

Strategie et tactique en chirurgie de la lepre.

Acta Lepr. 1984, 2, 55-63.

-BROWNEG.

Corticosteroias in leprosy a guid to their systemic use.

Lepr. Rev., 1964, 35, 157-163.

- BRYCESON A., PFALTZGRAFF R.E.

Leprosy, 2eme ed.

P. 72-76, Churchill Livingstone, Edinburgh, 1979.

- CHAUSSINAND R.

La lepre, 2eme ed. 1955.

Expansion Scientifique Frarn;aise, Paris.

- COLSTON M. J. et al.

Molecular biology of the mycobacteria.

Lepr. Rev., 1989, 60, 89-93.

- DANIELSEN D.C., BOECK C.W.

Our spedalsked-Udgivet after foranstalting af den kongelige Norske Reggeri Department for det

lndre, 1847, 1 Vol. et atlas Trykt hos. C. Grondehl - Christiana, Ed. Princeps Bergen.

Edition Frangaise : traite de la Spedalsked ou Elephantiasis des Grecs, 1848, J.-B, Baillere,

Paris.

- DATSUR D.K., ANTIA N.H., DIVEKAR S.C.

The facial nerve in leprosy. Pathology, pathogenesis, electromyography and 'clinical correlation.

Int. J. Lepr., 1966,34,118-138.

- DESIKAN K.V.

Viability of M leprae outside the human body.

Leprosy Review, 1977, 48, 231-235.

- FAGET G.H. POGGE R.C., JOHANSEN F.A., DINAN J.F., PREDJEAN B.M., ECCLESC.G.

The promin treatment of leprosy.

Public Health Reports, 1943, 58, 1729-1741.

- FAGET G.H., POGGE R.C., JOHANSEN F.A., FITE G.L., PREDJEAN B.M., GEMARF.

Present status of promin treatment of leprosy.

Int. J. Lepr., 1946, 14, 30-36.

- FROMM E., WITTMAN J.

Derivate des P-nitrophenols. ,

Berichte der Deutsche Chemischen Gesellschaft, 1908, 41, 2264-2273.

- GAYLORD H. BRENNANP.J.

Leprosy and leprosy bacillus : recent developments in characterization of antigens and immunology of the disease.

Ann. Rev. Mmicrobiol., 1987, 41, 645-675.

- GELBER R.H.

Activity of minocyline in M leprae infected mice.

J. Inf.Dis., 1987, 186, 236-239.

- GILBODY J.S.

Impact of multidrug therapy on the treatmen and control leprosy.

international journal of leprosy, 1991, 59, 458-478.

- GODAL T. MYRVANG B., STANFORD J.L. SAMUEL D.R.

Recent advances in the immunology of leprosy with special references to new approaches in immuno-prophylaxis.

Bull. Inst. Pasteur, 1974, 72, 273-310.

- GRAUWIN M.Y, MANE I. CARTEL J.L.

Pseudo-epitheliomatous hyperplasia in trophic ulcers in leprosy patients; A 28 cases study.

Lepr. Rev., 1996, 67, 203-207.

- GROSSET J.H., GUELPA-LAURAS C.C., PERANI E.G., BEOLETTO C.

Activity of ofloxacin against M. leprae in the mouse.

Int. J: Lepr. 1988, 56, 259-264.